| |
| |
| Exchange: |
|
| Security
Type: |
|
| Shares
Out: |
138,282,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
|
| Level
II Sector: |
|
| Level
III Sector: |
|
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Co.'s pipeline includes product candidates that utilize its understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to support critical components required for an anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents, and induction of an immune response via activators on effector cells in the tumor microenvironment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
50,000 |
50,000 |
50,000 |
50,000 |
| Total Buy Value |
$80,300 |
$80,300 |
$80,300 |
$80,300 |
| Total People Bought |
3 |
3 |
3 |
3 |
| Total Buy Transactions |
3 |
3 |
3 |
3 |
| Total Shares Sold |
7,142,856 |
7,142,856 |
7,142,856 |
7,142,856 |
| Total Sell Value |
$11,357,142 |
$11,357,142 |
$11,357,142 |
$11,357,142 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
2 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2025-05-27 |
4 |
B |
$2.11 |
$21,100 |
D/D |
10,000 |
6,480,825 |
2.81 |
- |
|
| Gordon Carl L |
Director |
– • • |
2025-04-09 |
4 |
S |
$1.59 |
$5,678,571 |
I/I |
(3,571,428) |
0 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2025-04-09 |
4 |
S |
$1.59 |
$5,678,571 |
I/I |
(3,571,428) |
0 |
|
- |
|
| Lerner Neil |
CHIEF ACCOUNTING OFFICER |
• – – |
2025-04-07 |
4 |
B |
$1.42 |
$28,400 |
D/D |
20,000 |
320,000 |
2.74 |
- |
|
| Anderman Jonathan |
Gen Counsel & Corporate Sec |
• – – |
2025-04-07 |
4 |
B |
$1.54 |
$30,800 |
D/D |
20,000 |
21,000 |
2.74 |
- |
|
| Schuetz Thomas J. |
CEO |
• • – |
2025-02-08 |
4 |
D |
$3.50 |
$145,905 |
D/D |
(41,687) |
6,470,825 |
|
- |
|
| Schuetz Thomas J. |
CEO |
• • – |
2025-01-09 |
4 |
D |
$1.86 |
$107,980 |
D/D |
(58,054) |
6,512,512 |
|
- |
|
| Lerner Neil |
VP FinanceOfficer |
• – – |
2024-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
300,000 |
|
- |
|
| Shin Barry |
CFO |
• – – |
2024-12-09 |
4 |
A |
$1.65 |
$660,000 |
D/D |
400,000 |
400,000 |
|
- |
|
| Anderman Jonathan |
Sr VP, Gen Counsel & Corp SecO |
• – – |
2024-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
| Bisker-Leib Vered |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-02-08 |
4 |
D |
$1.45 |
$71,337 |
D/D |
(49,198) |
3,124,426 |
|
- |
|
| Schuetz Thomas J. |
PRESIDENT |
• • – |
2024-02-08 |
4 |
D |
$1.45 |
$64,934 |
D/D |
(44,782) |
6,570,566 |
|
- |
|
| Bisker-Leib Vered |
Chief Executive Officer |
• • – |
2024-01-09 |
4 |
A |
$1.93 |
$3,383,531 |
D/D |
1,753,125 |
3,173,624 |
|
- |
|
| Schuetz Thomas J. |
President of R&D |
• • – |
2024-01-09 |
4 |
A |
$1.93 |
$1,230,375 |
D/D |
637,500 |
6,615,348 |
|
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-11-17 |
4 |
D |
$1.50 |
$66,038 |
D/D |
(44,025) |
5,977,848 |
|
- |
|
| Bisker-Leib Vered |
Chief Operating Officer |
• – – |
2023-11-17 |
4 |
D |
$1.50 |
$96,623 |
D/D |
(64,415) |
1,420,499 |
|
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-03-10 |
4 |
B |
$3.37 |
$33,700 |
D/D |
10,000 |
6,021,873 |
2.81 |
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-02-27 |
4 |
B |
$3.98 |
$79,600 |
D/D |
20,000 |
6,011,873 |
2.81 |
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-02-15 |
4 |
B |
$3.86 |
$77,200 |
D/D |
20,000 |
5,991,873 |
2.81 |
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
500,000 |
5,971,873 |
|
- |
|
| Bisker-Leib Vered |
Chief Operating Officer |
• – – |
2023-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
1,484,914 |
|
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-01-31 |
4 |
B |
$4.05 |
$81,000 |
D/D |
20,000 |
5,471,873 |
2.81 |
- |
|
| Schuetz Thomas J. |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-01-24 |
4 |
B |
$4.19 |
$83,800 |
D/D |
20,000 |
5,451,873 |
2.81 |
- |
|
| Bisker-Leib Vered |
Chief Operating Officer |
• – – |
2022-11-21 |
4 |
S |
$4.34 |
$69,592 |
D/D |
(16,035) |
1,084,914 |
|
- |
|
| Bisker-Leib Vered |
Chief Operating Officer |
• – – |
2022-11-18 |
4 |
S |
$4.40 |
$27,394 |
D/D |
(6,226) |
1,107,175 |
|
- |
|
72 Records found
|
|
Page 1 of 3 |
|
|
